Obinutuzumab activates FcγRI more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL)

Treatment with monoclonal antibodies has revolutionized clinical medicine, especially in the fields of cancer and immunology. One of the oldest antibodies, which is widely used for the treatment of lymphomas and autoimmune diseases, is the anti-CD20 antibody rituximab. In recent years, new antibodie...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncoimmunology
Egile Nagusiak: Elias, Shlomo, Kahlon, Shira, Kotzur, Rebecca, Kaynan, Noah, Mandelboim, Ofer
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Taylor & Francis 2018
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5980409/
https://ncbi.nlm.nih.gov/pubmed/29872553
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1428158
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak